EUVIMEDEUVIMED entdecken
Crossref

Kumatakenin drives renal and hepatic fibrosis via macrophage-to-myofibroblast transition

Shihong Chen, Boxiong Ni, Yixuan Gao, Weiyi Yuan, Xinrong Li, Yingchao Ying, Xianfei Zhou, Zhenzhai Cai, Xinliang Lu

International Immunopharmacology · 2026-07 · 180 · 116677

DOI: 10.1016/j.intimp.2026.116677 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026-07. Verfasst von Shihong Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027…. Hauptthemen laut MEDLINE: Macrophages, Liver Cirrhosis, Myofibroblasts, Renal Insufficiency, Chronic. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Macrophage-to-myofibroblast transition (MMT) is a pivotal driver of fibrogenesis and disease progression in both chronic kidney disease (CKD) and chronic liver disease (CLD). Kumatakenin, a bioactive compound extracted from traditional medicinal plants, has been shown to exhibit significant protective effects in various inflammatory and neoplastic diseases. However, there remains a considerable gap in understanding whether prolonged or high-dose usage of Kumatakenin could potentially induce adverse effects. This study demonstrates that Kumatakenin exacerbates renal and hepatic fibrosis and induces nephrotoxicity and hepatotoxicity by promoting MMT and the excessive deposition of extracellular matrix (ECM). Mechanistically, Kumatakenin regulates MMT in association with the activation of the Smad3 signaling, which plays a crucial role in fibrogenesis. Furthermore, the depletion of macrophages significantly prevents both nephrotoxicity and hepatotoxicity induced by Kumatakenin, highlighting the pivotal role of macrophages in this process. Therefore, our findings strongly suggest that Kumatakenin effectively modulates MMT, exacerbating CKD and CLD, and the severity of renal and hepatic fibrosis. These results provide a critical theoretical basis for thoroughly evaluating and considering the safety profile of Kumatakenin in clinical applications, emphasizing the need for caution in its therapeutic use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MacrophagesLiver CirrhosisMyofibroblastsRenal Insufficiency, ChronicKidneyAnimalsSmad3 ProteinHumansMiceMaleLiverMice, Inbred C57BLSignal TransductionFibrosis

Stichwörter der Autor:innen

Hepatic fibrosisKumatakeninMMTMacrophageRenal fibrosis

Substanzen

Smad3 ProteinSmad3 protein, mouse

Autor:innen und Institutionen

  • Department of Gastroenterology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, China.
  • Department of Thoracic Surgery, The Third Affiliated Hospital of Harbin Medical University, Harbin 150081, China.
  • Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China.
  • Department of Pediatrics, Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China.
  • Department of Hepatobiliary Surgery, Municipal Hospital Affiliated to Taizhou University, Taizhou, Zhejiang 318000, China. Electronic address: slyy_01740@tzc.edu.cn.
  • Department of Gastroenterology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, China. Electronic address: caizhenzhai@wmu.edu.cn.

Förderung

  • Natural Science Foundation of Zhejiang Province
  • National Natural Science Foundation of China

Zitieren

APA

Chen, S., Ni, B., Gao, Y., Yuan, W., Li, X., Ying, Y., Zhou, X., Cai, Z., & Lu, X. (2026). Kumatakenin drives renal and hepatic fibrosis via macrophage-to-myofibroblast transition. International Immunopharmacology, 180, 116677. https://doi.org/10.1016/j.intimp.2026.116677

Vancouver

Chen S, Ni B, Gao Y, Yuan W, Li X, Ying Y, et al. Kumatakenin drives renal and hepatic fibrosis via macrophage-to-myofibroblast transition. International Immunopharmacology. 2026;180:116677. doi:10.1016/j.intimp.2026.116677

BibTeX
@article{Chen2026,
  author = {Chen, Shihong and Ni, Boxiong and Gao, Yixuan and Yuan, Weiyi and Li, Xinrong and Ying, Yingchao and Zhou, Xianfei and Cai, Zhenzhai and Lu, Xinliang},
  title = {Kumatakenin drives renal and hepatic fibrosis via macrophage-to-myofibroblast transition},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {180},
  pages = {116677},
  doi = {10.1016/j.intimp.2026.116677}
}
Kostenlos starten →